Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

Company Overview - Immunome is focused on advancing antibody therapeutics for cancer and infectious diseases, developing proprietary biologic candidates for oncology and infectious disease indications [6][8] - As of February 17, 2026, Immunome's market capitalization is $2.08 billion, with a revenue of $9.68 million and a net income of -$222.74 million (TTM) [4] Transaction Details - On February 17, 2026, Opaleye Management Inc. sold all 3,185,000 shares of Immunome during the fourth quarter of 2025, with an estimated transaction value of $37.30 million [2][3] - Following the transaction, Immunome accounted for none of Opaleye's portfolio, which previously represented 5.3% of its 13F assets under management [3] Stock Performance - As of February 17, 2026, shares of Immunome were priced at $22.69, reflecting a 128.5% increase over the past year, delivering 106.26 percentage points of alpha versus the S&P 500 [3] - Immunome's stock has experienced significant volatility, with prices ranging from below $8/share to over $24/share in the past three years [7][9] - Despite a 158% increase over the past year, shares are down approximately 9% over the last two years [9]